Search results
We work fearlessly and go beyond because we care deeply about making a difference and changing lives. If you are inspired by helping others, driven to discover transformative medicines, and want a career that can make a difference, we want to hear from you! Search open positions. Where science meets humanity.
May 22, 2024 · Biogen Inc. agreed to acquire Human Immunology Biosciences Inc. for as much as $1.8 billion in a deal aimed at bolstering the biotechnology giant’s pipeline of immune disease treatments.
The potential to transform the lives of patients drives us at Biogen. Alzheimer’s Disease and Dementia. Our world-class neurology research and development organization is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
Jun 28, 2024 · June 28 (Reuters) - Eisai (4523.T) and Biogen (BIOAb.ST) have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on ...
Feb 13, 2024 · Feb 13 (Reuters) - Biogen (BIIB.O) on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off slowly, but said there are...
Nov 3, 2021 · MIT and Biogen have announced that they will collaborate with the goal to accelerate the science and action on climate change to improve human health. This collaboration is supported by a three-year, $7 million commitment from the company and the Biogen Foundation.
4 days ago · July 2, 2024. The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope, disappointment ...
